Bristol Myers, Bluebird Bio Blood Cancer Treatment Gets FDA Priority Review; BLUE Stock Up

Bristol Myers, Bluebird Bio Blood Cancer Treatment Gets FDA Priority Review; BLUE Stock Up

The CAR T cell therapy treatment Bristol Myers and Bluebird Bio are developing to treat the blood cancer multiple myeloma got FDA priority review, after earlier rejection; BMY stock rose.